Literature DB >> 19931652

Enhanced fibrinolysis by proteolysed coagulation factor Xa.

Kimberley Talbot1, Scott C Meixner, Edward L G Pryzdial.   

Abstract

We previously showed that coagulation factor Xa (FXa) enhances activation of the fibrinolysis zymogen plasminogen to plasmin by tissue plasminogen activator (tPA). Implying that proteolytic modulation occurs in situ, intact FXa (FXaalpha) must be sequentially cleaved by plasmin or autoproteolysis, producing FXabeta and Xa33/13, which acquire necessary plasminogen binding sites. The implicit function of Xa33/13 in plasmin generation has not been demonstrated, nor has FXaalpha/beta or Xa33/13 been studied in clot lysis experiments. We now report that purified Xa33/13 increases tPA-dependent plasmin generation by at least 10-fold. Western blots confirmed that in situ conversion of FXaalpha/beta to Xa33/13 correlated to enhanced plasmin generation. Chemical modification of the FXaalpha active site resulted in the proteolytic generation of a product distinct from Xa33/13 and inhibited the enhancement of plasminogen activation. Identical modification of Xa33/13 had no effect on tPA cofactor function. Due to its overwhelming concentration in the clot, fibrin is the accepted tPA cofactor. Nevertheless, at the functional level of tPA that circulates in plasma, FXaalpha/beta or Xa33/13 greatly reduced purified fibrin lysis times by as much as 7-fold. This effect was attenuated at high levels of tPA, suggesting a role when intrinsic plasmin generation is relatively low. FXaalpha/beta or Xa33/13 did not alter the apparent size of fibrin degradation products, but accelerated the initial cleavage of fibrin to fragment X, which is known to optimize the tPA cofactor activity of fibrin. Thus, coagulation FXaalpha undergoes proteolytic modulation to enhance fibrinolysis, possibly by priming the tPA cofactor function of fibrin. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931652     DOI: 10.1016/j.bbapap.2009.11.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Thrombolysis by chemically modified coagulation factor Xa.

Authors:  E L G Pryzdial; S C Meixner; K Talbot; L J Eltringham-Smith; J R Baylis; F M H Lee; C J Kastrup; W P Sheffield
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

2.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes.

Authors:  Jennifer L Newell-Caito; Malabika Laha; Anthony C Tharp; Jonathan I Creamer; Hong Xu; Ashoka A Maddur; Guido Tans; Paul E Bock
Journal:  J Biol Chem       Date:  2011-09-12       Impact factor: 5.157

Review 4.  The inflammatory actions of coagulant and fibrinolytic proteases in disease.

Authors:  Michael Schuliga
Journal:  Mediators Inflamm       Date:  2015-03-24       Impact factor: 4.711

5.  Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.

Authors:  Haixin Li; Ying Huang; Xian Wu; Ting Wu; Ying Cao; Qimei Wang; Yuchang Qiu; Weiming Fu; Qun Zhang; Jianxin Pang
Journal:  Drug Des Devel Ther       Date:  2018-05-23       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.